Logo image of ACOG.CA

Alpha Cognition Inc (ACOG.CA) Stock Fundamental Analysis

TSX-V:ACOG - TSX Venture Exchange - CA02074J2048 - Common Stock - Currency: CAD

0.39  -0.06 (-14.29%)

Fundamental Rating

1

Overall ACOG gets a fundamental rating of 1 out of 10. We evaluated ACOG against 25 industry peers in the Biotechnology industry. ACOG may be in some trouble as it scores bad on both profitability and health. ACOG has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ACOG had negative earnings in the past year.
In the past year ACOG has reported a negative cash flow from operations.
ACOG.CA Yearly Net Income VS EBIT VS OCF VS FCFACOG.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -5M -10M -15M

1.2 Ratios

The Return On Assets of ACOG (-239.04%) is worse than 80.65% of its industry peers.
ACOG's Return On Equity of -839.02% is in line compared to the rest of the industry. ACOG outperforms 45.16% of its industry peers.
Industry RankSector Rank
ROA -239.04%
ROE -839.02%
ROIC N/A
ROA(3y)-210.28%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ACOG.CA Yearly ROA, ROE, ROICACOG.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 -10K -20K -30K

1.3 Margins

ACOG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACOG.CA Yearly Profit, Operating, Gross MarginsACOG.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for ACOG has been increased compared to 1 year ago.
The debt/assets ratio for ACOG is higher compared to a year ago.
ACOG.CA Yearly Shares OutstandingACOG.CA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 20M 40M 60M
ACOG.CA Yearly Total Debt VS Total AssetsACOG.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -17.23, we must say that ACOG is in the distress zone and has some risk of bankruptcy.
ACOG has a Altman-Z score of -17.23. This is in the lower half of the industry: ACOG underperforms 61.29% of its industry peers.
ACOG has a Debt/Equity ratio of 0.89. This is a neutral value indicating ACOG is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.89, ACOG is in line with its industry, outperforming 48.39% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF N/A
Altman-Z -17.23
ROIC/WACCN/A
WACCN/A
ACOG.CA Yearly LT Debt VS Equity VS FCFACOG.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 5M -5M

2.3 Liquidity

ACOG has a Current Ratio of 2.04. This indicates that ACOG is financially healthy and has no problem in meeting its short term obligations.
ACOG has a Current ratio (2.04) which is comparable to the rest of the industry.
A Quick Ratio of 2.04 indicates that ACOG has no problem at all paying its short term obligations.
ACOG's Quick ratio of 2.04 is in line compared to the rest of the industry. ACOG outperforms 48.39% of its industry peers.
Industry RankSector Rank
Current Ratio 2.04
Quick Ratio 2.04
ACOG.CA Yearly Current Assets VS Current LiabilitesACOG.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.26% over the past year.
EPS 1Y (TTM)12.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.47%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACOG. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACOG.CA Price Earnings VS Forward Price EarningsACOG.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACOG.CA Per share dataACOG.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.05 -0.1 -0.15 -0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ACOG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Alpha Cognition Inc

TSX-V:ACOG (10/6/2023, 7:00:00 PM)

0.39

-0.06 (-14.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap33.89M
Analysts76.67
Price Target3.06 (684.62%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 18.79
P/tB 34.18
EV/EBITDA N/A
EPS(TTM)-0.22
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0
BVpS0.02
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -239.04%
ROE -839.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-210.28%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.04
Quick Ratio 2.04
Altman-Z -17.23
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)29.18%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.47%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-69.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-71.59%
OCF growth 3YN/A
OCF growth 5YN/A